Neoplasms

Digestive System Diseases

All Conditions

Rectal Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Intestinal Diseases

Rectal Diseases

Antineoplastic Agents

All Drugs and Chemicals

Capecitabine

Immune Checkpoint Inhibitors

Tislelizumab

Raltitrexed

Oxaliplatin

Antineoplastic Agents, Immunological

The blood supplying artery of the tumor is selected for drug injection with Oxaliplatin 85mg/m2 combined Raltitrexed 3mg/m2. After drug injection, gelatin sponge is used for embolization.

Arterial chemoembolization

Tislelizumab Injection 200mg i.v. q3w, A total of 3 cycles are administered.

Tislelizumab Injection

Capecitabine 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, i.v. day 1 Cycles are repeated on day 22. A total of 3 cycles are administered.

XELOX

Pelvic MRI

Surgical treatment for patients who meet the surgical conditions

Laparoscopic radical resection of rectal cancer

Yiqun Fan

Rectal cancer is one of the common malignant tumors of the digestive tract. Some patients with rectal cancer are already advanced tumors when they are first diagnosed. At this time, the tumor has local infiltration, the probability of recurrence and metastasis after surgical resection is high, and even radical tumor resection cannot be performed. Neoadjuvant chemotherapy and radiotherapy have become one of the important treatment methods for these patients to increase the rate of radical tumor resection. However, a series of side effects of neoadjuvant radiotherapy can even continue after the end of radiotherapy, and even increase the incidence of postoperative complications. Superselective arterial interventional chemotherapy has been widely used in preoperative neoadjuvant chemotherapy for various tumors, and its efficacy in rectal cancer has also been confirmed. In addition, as a hot spot in tumor treatment, tumor immunotherapy has shown exciting effects in the NICHE study of neoadjuvant immunotherapy before colon cancer surgery. Moreover, Oxaliplatin is a classic chemotherapeutic drug that induces Immunogenic cell death effects, which induce antitumor immunity.

Therefore, in order to optimize the preoperative neoadjuvant therapy plan, the investigators propose a treatment method of superselective arterial chemoembolization combined with immunotherapy and systemic chemotherapy, in order to obtain better preoperative conversion therapy effect and reduce the adverse reactions of neoadjuvant therapy.

Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer

Phase Ⅱ Clinical Trial of Neoadjuvant Arterial Embolization Chemotherapy Combined Immune Checkpoint Inhibitor for Locally Advanced Rectal Cancer: A Single Arm Prospective Sturdy

Tumor regression on imaging after neoadjuvant therapy

There is no histological evidence of malignancy in the primary tumor and metastatic regional lymph nodes, or there is only a carcinoma in situ component

Time from postoperative disease-free survival to disease recurrence or metastasis

Tumor regression on pathology after neoadjuvant therapy

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer	NCT05420584	Rectal Neoplasm...	Arterial chemoe... Tislelizumab In... XELOX Pelvic MRI Laparoscopic ra...	18 Years - 75 Years	The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer	NCT05420584	Rectal Neoplasm...	Arterial chemoe... Tislelizumab In... XELOX Pelvic MRI Laparoscopic ra...	18 Years - 75 Years	The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Spots Global Cancer Trial Database for arterial chemoembolization